Its use alongside ACEi/ARB, SGLT2 inhibitors and mineralocorticoid antagonists will help form the pillars of treatment for delaying the progression of CKD and reducing cardiovascular mortality. Aisling McMahon, executive director of research at Kidney Research UK, said: The results of the FLOW trial indicate semaglutide could improve quality of life for patients living with diabetes and CKD because they might be able to delay or avoid needing dialysis or transplantation, but importantly, it also showed that it reduced the risk of death from any cause
Skrobucha A, Pindlowski P, Krajewska N, Grabowski M, Jonik S
Bone Density Enhancement Growth hormone influences bone metabolism by promoting osteoblast activity, which is responsible for bone formation, and inhibiting osteoclast function, which is involved in bone resorption (3)
Acta Diabetol 2014
Before starting any new weight loss treatment or combination of therapies, schedule a consultation with our provider